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Midlife insulin resistance (IR) has previously been shown to be associated with lower cerebral blood 
flow (CBF), and is a potentially modifiable risk factor for dementia. The Blood Flow Improvement Trial 
(BFiT), NCT03117829 , tested a 12 week carbohydrate restricted diet (CRD) and exercise behavioral 
intervention to reverse IR, and aimed to 1) determine the extent to which improving or normalizing 
glucose homeostasis improves CBF and cognitive function in individuals with IR, 2) determine whether 
participants continue to maintain improved or normalized glycemic control for 6 months, and 3) 
determine changes in the human metabolome as individuals improve or normalize IR and glucose 
homeostasis through diet and exercise. 
Method 
Participants were recruited from the Wisconsin Alzheimer’s Disease Research Center and screened for 
metabolic risk factor eligibility based on the criteria shown in Table 1. The design involved a 12 week 
diet and exercise intervention focused on self-monitoring to promote adherence. Exercise was 
conducted in a supervised group setting 3 days/week for 50 minutes and participants were instructed 
to exercise on their own an additional 2 days/week. Participants followed a CRD and monitored their 
own blood glucose with the goal of achieving and maintaining fasting blood glucose <100 mg/dL. 
Participants underwent baseline, 12 week, and 6 month procedures including urine and blood 
labs/metabolomics, cognitive testing, fitness testing, and blood flow imaging via MRI (Table 2). 
Result 
The enrollment goal was 40 participants. 118 individuals were screened for eligibility, and 72.5% of the 
target enrollment was met; of those participants, nearly 80% completed the 12 week intervention. Of 
the 23 participants that completed the intervention, mean attendance was 70% for supervised exercise 
sessions and 81% for weekly behavioral coaching sessions. Figure 1 summarizes screening, enrollment, 
and procedure completion. 
Conclusion 
IR may be a modifiable risk factor for dementia. The BFiT pilot trial was designed to test the feasibility 
of exercise and CRD to reduce IR and improve brain blood flow in middle-aged adults. Reasonable 
enrollment and completion N were achieved. Future analysis will center on barriers to enrollment and 
adherence, as well as analysis of the primary and secondary outcome measures. 
 
FIGURE 1 
TABLE 1.  Metabolic Eligibility Criteria 
Option 1 Option 2 (both) Option 3 (any 3) 
Fasting blood 
glucose of 100 mg/dl 
or greater 
Waist circumference greater than 40 
inches for men and 35 inches for 
women 
Fasting triglycerides greater than 150 
mg/dl 
 Fasting blood glucose of 100 mg/dl 
or greater 
Fasting HDL less than 40 mg/dl for men 
and 50 mg/dl for women 
  Blood pressure greater than 130/85 
mm/Hg (systolic and/or diastolic above 
the cutoff) 
  Waist circumference greater than 40 
inches for men and 35 inches for women 
 
TABLE 2.  Baseline and Post-Intervention Procedures 
Procedure Details 
MRI scan ~45 minute protocol completed on a SIGNA PET/MR 3-Tesla scanner with 8-
channel head coil. Scans included Arterial Spin Labelling Perfusion, 4D Flow, 
Volumetric Tl -wieghted 
MRI, and T2FLAIR . 




California Verbal Learning Test II; Delis Kaplan Executive Function System Test 
Exercise Testing 6-minute walk test· Graded maximal exercise test 
Clinical visit Fasting blood and urine sample (12 hour fast); height, weight, anthropomorphic 
measures using DC-430U Tanita body composition analyzer scale 
 
 
